United States HER2-Positive Breast Cancer Market was valued at USD 8.5 Billion in 2022 and is projected to reach USD 12.9 Billion by 2030, growing at a CAGR of 6.5% from 2024 to 2030.
The US HER2-Positive Breast Cancer Market is witnessing significant growth due to advancements in treatments and increasing demand for more effective therapies. HER2-positive breast cancer is a subtype of breast cancer characterized by the overexpression of the HER2 protein, which promotes the growth of cancer cells. In the United States, the market for HER2-positive breast cancer therapies has become a focal point for pharmaceutical and biotechnology companies as they aim to develop and supply targeted treatments that are more efficient and personalized for patients.
The requirement for targeted therapies has grown substantially, particularly as researchers and healthcare professionals aim to improve patient outcomes. Innovative therapies such as HER2-targeted monoclonal antibodies, tyrosine kinase inhibitors, and vaccines are gaining traction in the market. These therapies are being increasingly adopted due to their precision in targeting cancer cells while minimizing damage to surrounding healthy tissues. As the prevalence of HER2-positive breast cancer remains a significant concern in the US, both the pharmaceutical and medical industries are under pressure to deliver cutting-edge solutions.
Industries involved in the HER2-positive breast cancer market are focused on research and development (R&D), aiming to discover new ways to combat the disease more effectively. Biopharmaceutical companies are investing heavily in R&D to innovate treatments that can extend the lives of patients while also improving their quality of life. Additionally, advancements in personalized medicine, which tailors treatment to an individual's genetic makeup, are expected to play a key role in the future growth of the market.
In the US, the HER2-positive breast cancer market also faces challenges related to affordability and accessibility of these specialized therapies. As the cost of advanced treatments remains high, there is increasing demand for more affordable solutions that can provide equal or better efficacy. Along with this, the need for improved patient education and awareness about the benefits of these therapies is also rising.
Overall, the HER2-positive breast cancer market in the United States continues to evolve, driven by continuous innovations in treatment options and a growing demand for more effective therapies. The combination of cutting-edge research and industry collaboration will play a crucial role in shaping the future of breast cancer care, making it more personalized and accessible to those who need it most.
Get an In-Depth Research Analysis of the US HER2-Positive Breast Cancer Market Size And Forecast [2025-2032]
Â
Pfizer (Pharmacia and Upjohn Company)
Novartis
AstraZeneca Pharmaceuticals
Eli Lilly
Roche Group
Merck
Jiangsu HengRui Medicine
Odonate Therapeutics
Radius Pharmaceuticals
Immunomedics
Syndax Pharmaceuticals
Bayer
Eagle Pharmaceuticals
Merrimack Pharmaceuticals
GlaxoSmithKline
Millennium Pharmaceuticals
Â
By the year 2030, the scale for growth in the market research industry is reported to be above 120 billion which further indicates its projected compound annual growth rate (CAGR), of more than 5.8% from 2023 to 2030. There have also been disruptions in the industry due to advancements in machine learning, artificial intelligence and data analytics There is predictive analysis and real time information about consumers which such technologies provide to the companies enabling them to make better and precise decisions. The Asia-Pacific region is expected to be a key driver of growth, accounting for more than 35% of total revenue growth. In addition, new innovative techniques such as mobile surveys, social listening, and online panels, which emphasize speed, precision, and customization, are also transforming this particular sector.
Get Discount On The Purchase of the US HER2-Positive Breast Cancer Market Size And Forecast [2025-2032]
Growing demand for below applications around the world has had a direct impact on the growth of the US HER2-Positive Breast Cancer Market
Immunohistochemistry (IHC)
Fluorescence in situ hybridization (FISH)
Polymerase chain reaction (PCR)
Chemotherapy
Targeted Therapy
Hormonal Therapy
Surgical Therapy
Monoclonal Antibodies
Small Molecule Inhibitors
Antibody-Drug Conjugates (ADC)
Trastuzumab (Herceptin)
Ado-Trastuzumab Emtansine (Kadcyla)
Perjeta (Pertuzumab)
Lapatinib
Hospitals
Ambulatory Surgical Centers
Specialized Cancer Treatment Centers
US (United States, US and Mexico)
Europe (Germany, UK, France, Italy, Russia, Turkey, etc.)
Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)
South America (Brazil, Argentina, Columbia, etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
For More Information or Query, Visit @ HER2-Positive Breast Cancer Market Research Analysis
1. Introduction of the US HER2-Positive Breast Cancer Market
Overview of the Market
Scope of Report
Assumptions
2. Executive Summary
3. Research Methodology of Verified Market Reports
Data Mining
Validation
Primary Interviews
List of Data Sources
4. US HER2-Positive Breast Cancer Market Outlook
Overview
Market Dynamics
Drivers
Restraints
Opportunities
Porters Five Force Model
Value Chain Analysis
5. US HER2-Positive Breast Cancer Market, By Type
6. US HER2-Positive Breast Cancer Market, By Application
7. US HER2-Positive Breast Cancer Market, By Geography
US
Europe
Asia Pacific
Rest of the World
8. US HER2-Positive Breast Cancer Market Competitive Landscape
Overview
Company Market Ranking
Key Development Strategies
9. Company Profiles
10. Appendix
About Us: Verified Market Reports
Verified Market Reports is a leading US Research and Consulting firm servicing over 5000+ US clients. We provide advanced analytical research solutions while offering information-enriched research studies. We also offer insights into strategic and growth analyses and data necessary to achieve corporate goals and critical revenue decisions.
Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance using industrial techniques to collect and analyze data on more than 25,000 high-impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.
Contact us:
Mr. Edwyne Fernandes
US: +1 (650)-781-4080
US Toll-Free: +1 (800)-782-1768
Website: https://www.verifiedmarketreports.com/